<DOC>
	<DOCNO>NCT01436643</DOCNO>
	<brief_summary>This prospective , multi-center , open-label study Relapsing-remitting Multiple Sclerosis ( RRMS ) patient mild moderate depression treat select serotonin reuptake inhibitor ( SSRI ) serotonin norepinephrine reuptake inhibitor ( SNRI ) antidepressants 16 week add-on fingolimod treatment . It design evaluate safety tolerability combination patient population base immunomodulatory treatment fingolimod .</brief_summary>
	<brief_title>Combination Antidepressants Fingolimod Relapsing-remitting Multiple Sclerosis ( RRMS ) Patients With Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Subjects relapse remit MS define 2010 revise McDonald criterion ( see Appendix 4 ) Patients Expanded Disability Status Scale ( EDSS ) score 06.5 ( see Appendix 8 ) Patients high disease activity despite treatment disease modify therapy ( &gt; 1 relapse previous year , &gt; 9 hyperintense T2 lesion &gt; 1 Gdenhancing lesion `` nonresponding '' could define unchanged increase relapse rate ongoing severe relapse compare previous year ) patient rapidly evolve severe RRMS ( e.g . &gt; 2 relapse disease progression one year &gt; 1 Gdenhancing lesion significant increase T2 lesion compare recent MRI ) Depression accord ICD10 criterion Mildmoderate depression assess BDIII score 1428 inclusively measure study inclusion fingolimod administer Patients history chronic disease immune system MS require systemic immunosuppressive treatment , know immunodeficiency syndrome . Patients Crohns disease ulcerative colitis exclude without exception History presence malignancy ( localize basal squamous cell carcinoma skin ) Patients active systemic bacterial , viral fungal infection , know AIDS , Hepatitis B , Hepatitis C infection positive HIV antibody , Hepatitis B surface antigen Hepatitis C antibody test Negative varicellazoster virus IgG antibody Screening Patients expect treated disease modify drug ( DMD ) study ( i.e . IFNÎ² , glatiramer acetate ) ; however washout need DMDs prior start fingolimod Patients treat : immunoglobulin and/or monoclonal antibody ( include natalizumab ) within 3 month prior start fingolimod Systemically applied corticosteroid adrenocorticotropic hormone ( ACTH ) within 1 month prior start fingolimod ( nevertheless , topical application permit ) ; Immunosuppressive medication azathioprine methotrexate , within 3 month prior start fingolimod ; Cyclophosphamid mitoxantrone within 6 month prior start fingolimod cladribine time current psychological pharmacological treatment depression ( MAO inhibitor particular ) , washout period 1 month prior start fingolimod require current treatment linezolid , washout period 1 month prior start fingolimod require Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Depression</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Venlafaxine</keyword>
	<keyword>Fluoxetine</keyword>
</DOC>